American Journal of Clinical Oncology · 1985 · 21 citations · 0 references
MedicineOncologyOtolaryngologyChemotherapyHearing AssessmentOtologyAdverse Effects Of ChemotherapyHearing ImpairmentHearing LossOtotoxicityOtotoxicity MonitoringToxicity Risk AssessmentAudiometric Threshold ShiftChemotherapy-induced OtotoxicityChemotherapy-related OtotoxicityChi-square TestCisplatin OtotoxicityCochlear ToxicityPlatinum-based OtotoxicityThreshold Shift Monitoring
Forty-four patients were evaluated for ototoxicity following treatment with the chemotherapeutic agent cis-platinum. Statistically significant hearing changes at 2,000 Hz (p less than 0.001); 4,000 Hz (p less than 0.05); and 8,000 Hz (p less than 0.001) were observed. Chi-square analysis demonstrated that at 8,000 Hz patients who had lower than average thresholds prior to chemotherapy were more likely to experience greater threshold shift than those patients whose pre-chemotherapy thresholds were higher than average. In this patient sample, there was no significant correlation shown between serum creatinine levels and ototoxicity.